| Objective: Esophageal carcinoma(EC) is one of the high incidence malignant tumors in our country, which is obviously characterised by geographical distribution. It has been fairly known that combined biological effects of multiple factors are involved in the carcinogenesis of esophageal epithelium. Therefore, it is necessary to look for a potential chemopreventive pathway or drugs to lower the risk of carcinogenesis of esopgageal epithelial cells.A large body of research has shown that the COX-2 level is increased in tissues of such tumors as esopgageal cancer, colorectal cancer, pancreas cancer. COX-2 overexpression can induce the incidence of tumors by regulating cellular apoptosis and stimulating the formation of capillaries. So, we can use COX-2 selective-inhibitors to treat the malignant tumors according to the target of COX-2. Large quantities of epidemiological studies have indicated that regular intake of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of gastrointestinal tract carcinomas, such as colorectal carcinoma, esophageal carcinoma, pancreas carcinoma. Thus it can be concluded that COX-2 inhibitors have chemopreventive effects.However, standard NSAIDs are nonselective in their inhibition, affecting both COX-1 and COX-2. Treatment with these agents is limited by normal tissue toxicity. The gastrointestinal tract is more particularly sensitive than other tissues, which is especially dependent on COX-1 for normal function. Therefore, considering it is COX-2 that is overexpressed in many tumor types, the recently developed selective COX-2 inhibitors may be amenable for use in antineoplastic therapy.Valdecoxib is the second generation selective COX-2 inhibitor. It has...
|
PDF Full Text Request